for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Varian Medical Systems, Inc.

VAR.N

Latest Trade

118.51USD

Change

3.10(+2.69%)

Volume

176,610

Today's Range

117.29

 - 

120.00

52 Week Range

89.62

 - 

150.05

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Varian Halcyon 2.0 Treatment System Receives China NMPA Approval

March 16 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN HALCYON 2.0 TREATMENT SYSTEM RECEIVES CHINA NMPA APPROVAL.

Varian Says COVID-19 Outbreak Will Negatively Impact Operating Results

March 9 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN PROVIDES AN UPDATE ON EXPECTED IMPACT FROM COVID-19.SEES Q2 2020 REVENUE $800 MILLION TO $825 MILLION.COVID-19 OUTBREAK WILL NEGATIVELY IMPACT COMPANY'S OPERATING RESULTS."CO'S OUTLOOK COULD SHIFT IF DYNAMICS OF COVID-19 OUTBREAK CHANGE MATERIALLY".VARIAN MEDICAL SYSTEMS - EXPERIENCING DELAYS IN HARDWARE, SOFTWARE INSTALLATIONS &ACCEPTANCE & IN DELIVERY OF INTERVENTIONAL ONCOLOGY PROCEDURES.VARIAN MEDICAL SYSTEMS - CO PRELIMINARILY ESTIMATES 7 TO 9 PERCENT REVENUE GROWTH FOR FISCAL YEAR 2020.COMPANY'S OUTLOOK COULD SHIFT IF DYNAMICS OF CORONAVIRUS OUTBREAK CHANGE MATERIALLY.VARIAN MEDICAL SYSTEMS - WILL PROVIDE FURTHER UPDATES TO GUIDANCE, INCLUDING EARNINGS AND CASH FLOW FROM OPERATIONS, DURING Q2 2020 EARNINGS.

Varian Medical Systems Posts Q1 Non-GAAP EPS Of $1.16

Jan 29 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN REPORTS RESULTS FOR FIRST QUARTER OF FISCAL YEAR 2020.Q1 NON-GAAP EARNINGS PER SHARE $1.16.Q1 GAAP EARNINGS PER SHARE $0.96.Q1 EARNINGS PER SHARE ESTIMATE $1.19 -- REFINITIV IBES DATA.NO CHANGE TO FISCAL YEAR 2020 GUIDANCE.QTRLY TOTAL COMPANY REVENUES GREW 12% IN DOLLARS, OR 13% IN CONSTANT CURRENCY, TO $829 MILLION.QTRLY ORGANIC REVENUES GREW 8%.

Varian Medical Systems Says CEO Dow Wilson's 2019 Total Compensation Was $9.4 Mln Versus $10.3 Mln In 2018

Dec 20 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN MEDICAL SYSTEMS SAYS CEO DOW R. WILSON'S 2019 TOTAL COMPENSATION WAS $9.4 MILLION VERSUS $10.3 MILLION IN 2018 – SEC FILING.VARIAN MEDICAL SYSTEMS - FOR FISCAL 2019, RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES WAS 86:1.

Varian Medical Systems Inc Announces Updates To Previously Reported GAAP Preliminary Financial Results For Its Q4 & Full Fiscal Year 2019

Nov 22 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN MEDICAL SYSTEMS INC - ANNOUNCED UPDATES TO PREVIOUSLY REPORTED GAAP PRELIMINARY FINANCIAL RESULTS FOR ITS Q4 & FULL FISCAL YEAR 2019.VARIAN MEDICAL SYSTEMS INC - PROJECTED FINANCIAL PERFORMANCE OF RECENTLY ACQUIRED ENDOCARE & ALICON BUSINESSES BETTER THAN PREVIOUSLY EXPECTED.VARIAN MEDICAL SYSTEMS INC - THERE IS NO IMPACT TO Q4 AND FY NON-GAAP FINANCIAL MEASURES.VARIAN MEDICAL SYSTEMS - INCREASE IN FAIR VALUE FROM ACQUISITIONS HAS RESULTED IN AN $18.6 MILLION INCREASE IN ACQUISITION-RELATED EXPENSES IN Q4 OF 2019.VARIAN MEDICAL SYSTEMS INC - UPDATED Q4 NET EARNINGS PER SHARE TO $0.77.

Varian Medical Systems Reports Q4 Non-GAAP Earnings Per Share Of $1.21

Oct 23 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN REPORTS RESULTS FOR FOURTH QUARTER AND FULL FISCAL YEAR 2019; APPOINTS NEW PRESIDENT OF INTERVENTIONAL ONCOLOGY SOLUTIONS AND NEW CHIEF FINANCIAL OFFICER.Q4 NON-GAAP EARNINGS PER SHARE $1.21.Q4 GAAP EARNINGS PER SHARE $0.97.Q4 EARNINGS PER SHARE ESTIMATE $1.21 -- REFINITIV IBES DATA.J. MICHAEL BRUFF, WILL SUCCEED BISCHOPING AS SENIOR VICE PRESIDENT, FINANCE & CHIEF FINANCE OFFICER.QTRLY TOTAL REVENUES GREW 10% IN DOLLARS, OR 11% IN CONSTANT CURRENCY, TO $879 MILLION.EFFECTIVE DECEMBER 1, CFO GARY BISCHOPING, JR., WILL TAKE ON A NEW ROLE AS PRESIDENT, INTERVENTIONAL ONCOLOGY SOLUTIONS.QTRLY TOTAL COMPANY REVENUES GREW 10% IN DOLLARS, OR 11% IN CONSTANT CURRENCY, TO $879 MILLION.Q4 REVENUE VIEW $858.5 MILLION -- REFINITIV IBES DATA.SEES FY 2020 NON-GAAP NET EARNINGS PER SHARE-DILUTED $5.30 TO $5.45.TARIFF EXCLUSIONS HAD A $21 MILLION BENEFIT TO REVENUES IN QUARTER.ENDED QUARTER WITH $531 MILLION IN CASH AND CASH EQUIVALENTS AND $412 MILLION IN DEBT.SEES FY 2020 REVENUE $3.515 BILLION TO $3.612 BILLION.

Varian Expects To Benefit From Linear Accelerator Tariff Exclusion In China

Sept 11 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN EXPECTS TO BENEFIT FROM LINEAR ACCELERATOR TARIFF EXCLUSION IN CHINA.VARIAN MEDICAL SYSTEMS INC - EXPECTS TO BE ELIGIBLE FOR A REFUND FROM TARIFFS THAT HAVE BEEN LEVIED SINCE ADDITIONAL TARIFFS WERE IMPLEMENTED.VARIAN MEDICAL - RECEIVED NOTICE FROM CHINA THAT MEDICAL LINEAR ACCELERATORS ARE EXCLUDED FROM ADDITIONAL TARIFFS CHINA IMPOSED ON U.S. PRODUCTS.VARIAN MEDICAL SYSTEMS INC - EXEMPTION WILL BECOME EFFECTIVE ON SEPTEMBER 17, 2019..VARIAN MEDICAL - WILL EVALUATE IF FURTHER COMMENTS NECESSARY AFTER COMPLETING ASSESSMENT OF IMPACT OF EXCLUSION, INCLUDING TIMING, PROCESS FOR REFUNDS.VARIAN MEDICAL SYSTEMS INC - EXCLUSION OF MEDICAL LINEAR ACCELERATORS IS RETROACTIVE.

Varian Announces Immaterial Impact Of Newly Proposed Tariffs

Aug 5 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN ANNOUNCES IMMATERIAL IMPACT OF NEWLY PROPOSED TARIFFS.VARIAN MEDICAL SYSTEMS - ESTIMATES NEWLY PROPOSED TARIFFS BY U.S. ON REMAINING CHINESE IMPORTS SHOULD HAVE IMMATERIAL FINANCIAL IMPACT.

Varian Q3 NON-GAAP Earnings Per Share $1.32

July 24 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN REPORTS RESULTS FOR THIRD QUARTER OF FISCAL YEAR 2019.Q3 NON-GAAP EARNINGS PER SHARE $1.32.Q3 GAAP EARNINGS PER SHARE $0.32.Q3 EARNINGS PER SHARE ESTIMATE $1.13 -- REFINITIV IBES DATA.QTRLY TOTAL COMPANY REVENUES GREW 16% IN DOLLARS, OR 19% IN CONSTANT CURRENCY, TO $826 MILLION.US/CHINA TARIFFS NEGATIVELY IMPACTED REVENUE GROWTH BY $10 MILLION OR 140 BASIS POINTS IN QUARTER.RAISING FY REVENUE GROWTH RANGE TO 9% TO 10%.NARROWING FY FORECAST FOR NON-GAAP NET EARNINGS PER DILUTED SHARE RANGE TO $4.58 TO $4.63.SEES 2019 REVENUES $3.18 BILLION TO $3.21 BILLION.FY2019 EARNINGS PER SHARE VIEW $4.68, REVENUE VIEW $3.15 BILLION -- REFINITIV IBES DATA.

Varian Says Asset Purchase Deal To Buy Boston Scientific Portfolio Of Embolic Bead Assets

July 2 (Reuters) - Varian Medical Systems Inc <VAR.N>::VARIAN TO EXPAND INTERVENTIONAL ONCOLOGY PORTFOLIO WITH PURCHASE OF EMBOLIC BEAD ASSET.VARIAN IS FINANCING PURCHASE PRICE OF $90 MILLION USING CASH AND PROCEEDS FROM BORROWINGS.VARIAN MEDICAL SYSTEMS - ASSET PURCHASE AGREEMENT TO ACQUIRE BOSTON SCIENTIFIC PORTFOLIO OF DRUG-LOADABLE MICROSPHERE AND BLAND EMBOLIC BEAD PRODUCTS.EXPECTS TRANSACTION TO HAVE AN IMMATERIAL IMPACT ON FISCAL YEAR 2019 FINANCIAL RESULTS.COMBINED ASSETS TO BE ACCRETIVE TO GAAP AND NON-GAAP EARNINGS PER SHARE IN FISCAL 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up